These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25003676)

  • 21. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses.
    Severino V; Dumonceau JM; Delhaye M; Moll S; Annessi-Ramseyer I; Robin X; Frossard JL; Farina A
    Gastroenterology; 2017 Aug; 153(2):495-504.e8. PubMed ID: 28479376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
    Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
    Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
    Zong D; Zeng Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Astronomically high CA 19-9 in a patient with a benign lesion.
    Rao NA; Satyaprakash BS
    S Afr J Surg; 2013 Oct; 51(4):151. PubMed ID: 24209706
    [No Abstract]   [Full Text] [Related]  

  • 28. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study.
    Weilert F; Bhat YM; Binmoeller KF; Kane S; Jaffee IM; Shaw RE; Cameron R; Hashimoto Y; Shah JN
    Gastrointest Endosc; 2014 Jul; 80(1):97-104. PubMed ID: 24559784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
    Lindberg B; Arnelo U; Bergquist A; Thörne A; Hjerpe A; Granqvist S; Hansson LO; Tribukait B; Persson B; Broomé U
    Endoscopy; 2002 Nov; 34(11):909-16. PubMed ID: 12430077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
    La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
    World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
    Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
    Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of biliary fibronectin for diagnosis of cholangiocarcinoma.
    Chen CY; Lin XZ; Tsao HC; Shiesh SC
    Hepatogastroenterology; 2003; 50(52):924-7. PubMed ID: 12845951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Björnsson E; Kilander A; Olsson R
    Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
    Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
    J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
    Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
    Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.
    Tshering G; Dorji PW; Chaijaroenkul W; Na-Bangchang K
    Am J Trop Med Hyg; 2018 Jun; 98(6):1788-1797. PubMed ID: 29637880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.